WO2010044543A3 - 단백질 키나제 억제제로서 헤테로사이클릭 화합물 - Google Patents

단백질 키나제 억제제로서 헤테로사이클릭 화합물 Download PDF

Info

Publication number
WO2010044543A3
WO2010044543A3 PCT/KR2009/004830 KR2009004830W WO2010044543A3 WO 2010044543 A3 WO2010044543 A3 WO 2010044543A3 KR 2009004830 W KR2009004830 W KR 2009004830W WO 2010044543 A3 WO2010044543 A3 WO 2010044543A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein kinase
heterocyclic compound
kinase inhibitor
compound
met
Prior art date
Application number
PCT/KR2009/004830
Other languages
English (en)
French (fr)
Other versions
WO2010044543A2 (ko
Inventor
김태성
이은경
김도영
박부만
박지연
주정재
Original Assignee
주식회사 네오팜
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 네오팜 filed Critical 주식회사 네오팜
Priority to JP2011532009A priority Critical patent/JP2012505874A/ja
Priority to AU2009304610A priority patent/AU2009304610B2/en
Priority to CN200980150189XA priority patent/CN102245595A/zh
Priority to US12/920,243 priority patent/US8957102B2/en
Priority to NZ592136A priority patent/NZ592136A/en
Priority to RU2011114487/04A priority patent/RU2011114487A/ru
Priority to EP09820693A priority patent/EP2336123A4/en
Priority to BRPI0920239A priority patent/BRPI0920239A2/pt
Priority to CA2739884A priority patent/CA2739884A1/en
Publication of WO2010044543A2 publication Critical patent/WO2010044543A2/ko
Publication of WO2010044543A3 publication Critical patent/WO2010044543A3/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

본 발명에 의하여, c-Met와 같은 성장 인자 수용체의 단백질 키나제 활성을 억제함으로써 항암제로서 유용하게 사용될 수 있는 신규 헤테로사이클릭 화합물, 상기 화합물을 포함하는 약학적 조성물 및 상기 화합물의 사용 방법이 제공된다. 또한, 본 발명의 상기 화합물을 포함하는 약학적 조성물은 암 이외에, 성장 인자 및 항-혈관형성 수용체, 예컨대 c-Met를 통해 작동하는 신호 전달 경로와 관련된 질환의 치료에 유용하게 사용될 수 있다.
PCT/KR2009/004830 2008-10-14 2009-08-28 단백질 키나제 억제제로서 헤테로사이클릭 화합물 WO2010044543A2 (ko)

Priority Applications (9)

Application Number Priority Date Filing Date Title
JP2011532009A JP2012505874A (ja) 2008-10-14 2009-08-28 タンパク質キナーゼとしての複素環化合物
AU2009304610A AU2009304610B2 (en) 2008-10-14 2009-08-28 Heterocyclic compound as protein kinase inhibitor
CN200980150189XA CN102245595A (zh) 2008-10-14 2009-08-28 作为蛋白质激酶抑制剂的杂环化合物
US12/920,243 US8957102B2 (en) 2008-10-14 2009-08-28 Heterocyclic compound as protein kinase inhibitor
NZ592136A NZ592136A (en) 2008-10-14 2009-08-28 Heterocyclic compound as protein kinase inhibitor
RU2011114487/04A RU2011114487A (ru) 2008-10-14 2009-08-28 Гетероциклические соединения как ингибиторы протеинкиназы
EP09820693A EP2336123A4 (en) 2008-10-14 2009-08-28 HETEROCYCLIC COMPOUND AS INHIBITOR OF PROTEIN KINASE
BRPI0920239A BRPI0920239A2 (pt) 2008-10-14 2009-08-28 compostos heterocíclicos como inibidores de proteínas quinases
CA2739884A CA2739884A1 (en) 2008-10-14 2009-08-28 Heterocyclic compounds as protein kinases inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2008-0100522 2008-10-14
KR20080100522 2008-10-14

Publications (2)

Publication Number Publication Date
WO2010044543A2 WO2010044543A2 (ko) 2010-04-22
WO2010044543A3 true WO2010044543A3 (ko) 2010-06-24

Family

ID=42107002

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/004830 WO2010044543A2 (ko) 2008-10-14 2009-08-28 단백질 키나제 억제제로서 헤테로사이클릭 화합물

Country Status (11)

Country Link
US (2) US8957102B2 (ko)
EP (1) EP2336123A4 (ko)
JP (1) JP2012505874A (ko)
KR (2) KR100961410B1 (ko)
CN (1) CN102245595A (ko)
AU (1) AU2009304610B2 (ko)
BR (1) BRPI0920239A2 (ko)
CA (1) CA2739884A1 (ko)
NZ (1) NZ592136A (ko)
RU (1) RU2011114487A (ko)
WO (1) WO2010044543A2 (ko)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2011119478A (ru) 2008-10-14 2012-11-27 Нин Си Соединения и способы применения
JP5583751B2 (ja) 2009-03-21 2014-09-03 クイ ニング アミノエステル誘導体、その塩、及び使用方法
RU2568258C2 (ru) 2011-02-28 2015-11-20 Саншайн Лейк Фарма Ко., Лтд Замещенные соединения хинолина и способы их использования
TWI520962B (zh) * 2012-06-29 2016-02-11 As the c-Met tyrosine kinase inhibitors novel fused pyridine derivatives
WO2014022117A1 (en) * 2012-07-28 2014-02-06 Calitor Sciences, Llc Substituted pyrazolone compounds and methods of use
US8975282B2 (en) 2012-07-28 2015-03-10 Sunshine Lake Pharma Co., Ltd. Substituted pyrazolone compounds and methods of use
US9447105B2 (en) 2013-01-24 2016-09-20 Council Of Scientific & Industrial Research Triazine compounds and a process for preparation thereof
KR101598664B1 (ko) * 2013-09-04 2016-03-02 씨제이헬스케어 주식회사 피롤로피리다진 유도체를 포함하는 단백질 키나제 억제제
CN104876941B (zh) * 2014-02-28 2019-02-01 南京汇诚制药有限公司 稠合三环类化合物及其应用
CA2946538A1 (en) 2014-04-04 2015-10-08 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
EP3134088B1 (en) 2014-04-22 2019-04-10 Calitor Sciences, LLC Bicylcic pyrazolone compounds and methods of use
TW201613919A (en) 2014-07-02 2016-04-16 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
WO2018116072A1 (en) 2016-12-20 2018-06-28 Pi Industries Ltd. Heterocyclic compounds
WO2019101178A1 (zh) 2017-11-24 2019-05-31 南京明德新药研发股份有限公司 作为c-MET/AXL抑制剂的尿嘧啶类化合物
CN107973362A (zh) * 2017-12-22 2018-05-01 中国地质大学（武汉） 一种基于水铝钙石同时去除水中氟和砷酸盐的方法及装置
CN110511218A (zh) * 2018-05-21 2019-11-29 中国科学院上海药物研究所 一类并环吡唑啉酮甲酰胺类化合物及其制备方法、药物组合物和用途
TW202039481A (zh) 2018-12-21 2020-11-01 美商西建公司 Ripk2之噻吩并吡啶抑制劑
CN113248507A (zh) * 2020-02-09 2021-08-13 上海茂晟康慧科技有限公司 瑞德西韦关键中间体7-卤代吡咯并[1,2-f][1,2,4]三嗪-4-胺的合成方法
CN114573553B (zh) * 2022-01-27 2023-11-10 广州六顺生物科技有限公司 杂芳环类衍生物及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008052974A1 (en) * 2006-10-30 2008-05-08 Novartis Ag 3-amino-pyrazole-4-carboxamide derivatives useful as inhibitors of protein kinases
US20080234268A1 (en) * 2007-01-09 2008-09-25 Amgen Inc. Bis-aryl amide derivatives and methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050288290A1 (en) * 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
MX2008011220A (es) * 2006-03-07 2008-09-11 Array Biopharma Inc Compuestos de pirazol heterobiciclicos y metodos de uso.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008052974A1 (en) * 2006-10-30 2008-05-08 Novartis Ag 3-amino-pyrazole-4-carboxamide derivatives useful as inhibitors of protein kinases
US20080234268A1 (en) * 2007-01-09 2008-09-25 Amgen Inc. Bis-aryl amide derivatives and methods of use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LONGBIN LIU ET AL.: "Discovery of Potent, Selective, and Orally Bioavailable c-Met Inhibitor", J. MED. CHEM., vol. 51, July 2008 (2008-07-01), pages 3688 - 3691, XP008140337 *
See also references of EP2336123A4 *
YIHONG ZHANG ET AL.: "Identification of a Novel Recepteur d'Origine Nantais/c-Met Small- Molecule Kinase Inhibitor with Antitumor Activity In vivo", CANCER RESEARCH, vol. 68, no. 16, 15 August 2008 (2008-08-15), pages 6680 - 6687, XP008140336 *

Also Published As

Publication number Publication date
EP2336123A4 (en) 2012-05-02
BRPI0920239A2 (pt) 2019-09-24
CN102245595A (zh) 2011-11-16
KR20100051782A (ko) 2010-05-18
AU2009304610A1 (en) 2010-04-22
EP2336123A2 (en) 2011-06-22
JP2012505874A (ja) 2012-03-08
US20120289509A1 (en) 2012-11-15
NZ592136A (en) 2011-12-22
RU2011114487A (ru) 2012-11-27
US20110183983A1 (en) 2011-07-28
AU2009304610B2 (en) 2011-09-15
WO2010044543A2 (ko) 2010-04-22
KR100961410B1 (ko) 2010-06-09
US8957102B2 (en) 2015-02-17
CA2739884A1 (en) 2010-04-22
KR20100041669A (ko) 2010-04-22

Similar Documents

Publication Publication Date Title
WO2010044543A3 (ko) 단백질 키나제 억제제로서 헤테로사이클릭 화합물
WO2010005876A3 (en) Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
WO2011121418A9 (en) 4 - aminopyrimidine derivatives and their as as adenosine a2a receptor antagonists
WO2008060907A3 (en) Pyrrolo-pyridine kinase inhibitors
WO2008083367A3 (en) Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
UA100227C2 (uk) Заміщені n-фенілметил-5-оксопролін-2-аміди як антагоністи p2x7-рецептора та їх застосування
EA200901133A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
MX2009008953A (es) Compuestos como inhibidores de angiogenesis.
MX2009009843A (es) Compuestos espiro sustituidos como inhibidores de la angiogenesis.
WO2010120994A3 (en) Ureidoaryl-and carbamoylaryl-morpholino- pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis
MX2012013082A (es) Derivados de 2-aminopiridina utiles como iinhibidores de cinasa atr.
MX2011006503A (es) Derivados de pirazina utiles como inhibidores de la cinasa de atr.
EA200901138A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
EA201001687A1 (ru) Производные имидазопиридина в качестве ингибиторов активиноподобной рецепторной киназы ( alk-4 или alk-5 )
EA200970402A1 (ru) Триазолопиридазиновые модуляторы протеинкиназ
WO2011143425A3 (en) Compounds useful as inhibitors of atr kinase
EA201400701A1 (ru) Замещенные соединения пиразоло[1,5-a]пиридина в качестве ингибиторов тропомиозинрецепторной киназы (trk)
WO2011143423A3 (en) Compounds useful as inhibitors of atr kinase
HK1131608A1 (en) Pyridinone compounds
MX2011004953A (es) Compuestos utiles como inhibidores de cinasa atr.
WO2008051808A3 (en) Bicyclic triazoles as protein kinase modulators
WO2008021849A3 (en) Novel compounds as antagonists or inverse agonists at opioid receptors
WO2008078100A3 (en) Tricyclic amine derivatives as protein tyrosine kinase inhibitors
EA200900983A1 (ru) Соединения и композиции в качестве ингибиторов киназы
WO2011033265A8 (en) Pharmaceutical compounds

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980150189.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09820693

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009820693

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12920243

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1254/KOLNP/2011

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2739884

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 592136

Country of ref document: NZ

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011532009

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2009304610

Country of ref document: AU

Date of ref document: 20090828

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2011114487

Country of ref document: RU

ENP Entry into the national phase

Ref document number: PI0920239

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110414